趋化因子与肺癌

doi:10.3760/cma.j.issn.1673-422X.2016.10.016

摘要/Abstract

摘要： 趋化因子与其相应的受体作用，广泛参与生物活动及病理过程。研究发现多种肿瘤细胞都过表达功能性的趋化因子。在肺癌中，趋化因子参与了其增殖、凋亡、侵袭和转移等过程。肺癌过表达的趋化因子及其受体，可作为明确的靶向目标进行针对性的抗肿瘤治疗。

关键词: 趋化因子类, 受体, 趋化因子, 肺肿瘤, 肿瘤转移

Abstract: Chemokines and chemokine receptors involve in biological activity and pathological process widely. It has been reported that many tumor cells overexpress functional chemokines. In lung cancer, chemokines involve in its proliferation, apoptosis, invasion and metastasis. Chemokines and chemokine receptor overexpressed in lung cancer can be used as specific target for pertinent antitumor treatment.

Key words: Chemotactic factors, Receptors, chemokine, Lung neoplasms, Neoplasm metastasis

李国栋,欧阳伟炜,苏胜发,马筑,李青松,王羽,卢冰. 趋化因子与肺癌[J]. 国际肿瘤学杂志, 2016, 43(10): 787-790.

Li Guodong, Ouyang Weiwei, Su Shengfa, Ma Zhu, Li Qingsong, Wang Yu, Lu Bing. Chemokines and lung cancer[J]. Journal of International Oncology, 2016, 43(10): 787-790.

参考文献

［1］ Rossi D, Zlotnik A. The biology of chemokines and their receptors［J］. Annu Rev Immunol, 2000, 18: 217242. ［2］ Wrnle M, Schmid H, Merkle M, et al. Effects of chemokines on proliferation and apoptosis of human mesangial cells［J］. BMC Nephrol, 2004, 5(5): 8. DOI: 10.1186/1471236958. ［3］ Beider K, Abraham M, Begin M, et al. Interaction between CXCR4 and CCL20 pathways regulates tumor growth［J］. PLoS One, 2009, 4(4): e5125. DOI: 10.1371/journal.pone.0005125. ［4］高永静, 张志军, 曹德利. 趋化因子介导的神经炎症反应和神经病理性疼痛［J］. 中国细胞生物学学报, 2014, 3(3): 297307. ［5］张静, 邓向红. 趋化因子与中枢神经系统感染［J］. 临床医学工程, 2014 (5): 668669, 672. DOI: 10.3969/j.issn.16744659.2014.05.0668. ［6］段冬冬, 宋泽庆. 趋化因子与结核性胸膜炎［J］. 医学理论与实践, 2014, 27(17): 22632265. ［7］刘相良, 原铭贞, 刘笑玎, 等. 趋化因子及其受体在急性肺损伤中作用的研究进展［J］. 吉林大学学报(医学版), 2014(4): 908912. DOI: 10.13481/j.1671587x.20140445. ［8］ Molina JR, Yang P, Cassivi SD, et al. Nonsmall cell lung cancer: epidemiology, risk factors, treatment, and survivorship［J］. Mayo Clin Proc, 2008, 83(5): 584594. DOI: 10.4065/83.5.584. ［9］ Aldinucci D, Gloghini A, Pinto A, et al. The classical Hodgkin′s lymphoma microenvironment and its role in promoting tumour growth and immune escape［J］. J Pathol, 2010, 221(3): 248263. DOI: 10.1002/path.2711. ［10］ Meadows SA, Vega F, Kashishian A, et al. PI3Kδ inhibitor, GS1101 (CAL101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma［J］. Blood, 2012, 119(8): 18971900. DOI: 10.1182/blood201110386763. ［11］杨璐, 李恒平, 刘振华, 等. 趋化因子与炎症、前列腺癌的关系的研究［J］. 现代预防医学, 2015, 42(5): 952956. ［12］唐威, 李劲东. 甲状腺癌组织中趋化因子4受体和趋化因子7受体的表达情况及临床病理意义［J］. 标记免疫分析与临床, 2015, 22(5): 450452, 473. DOI: 10.11748/bjmy.issn.10061703.2015.05.026. ［13］ Mukaida N, Baba T. Chemokines in tumor development and progression［J］. Exp Cell Res, 2012, 318(2): 95102. DOI: 10.1016/j.yexcr.2011.10.012. ［14］ Xu Y, Liu L, Qiu X, et al. CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human nonsmall cell lung cancer cells［J］. PLoS One, 2011, 6(6): e21119. DOI: 10.1371/journal.pone.0021119. ［15］ Xu Y, Liu L, Qiu X, et al. CCL21/CCR7 prevents apoptosis via the ERK pathway in human nonsmall cell lung cancer cells［J］. PLoS One, 2012, 7(3): e33262. DOI: 10.1371/journal.pone.0033262. ［16］ Imai H, Sunaga N, Shimizu Y, et al. Clinicopathological and therapeutic significance of CXCL12 expression in lung cancer［J］. Int J Immunopathol Pharmacol, 2010, 23(1): 153164. ［17］ Wu FY, Fan J, Tang L, et al. Atypical chemokine receptor D6 inhibits human nonsmall cell lung cancer growth by sequestration of chemokines［J］. Oncol Lett, 2013, 6(1): 9195. DOI: 10.3892/ol.2013.1358. ［18］ Hu W, Liu Y, Zhou W, et al. CXCL16 and CXCR6 are coexpressed in human lung cancer in vivo and mediate the invasion of lung cancer cell lines in vitro［J］. PLoS One, 2014, 9(6): e99056. DOI: 10.1371/journal.pone.0099056. ［19］ Saintigny P, Massarelli E, Lin S, et al. CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma［J］. Cancer Res, 2013, 73(2): 571582. DOI: 10.1158/00085472.CAN120263. ［20］ Gupta P, Sharma PK, Mir H, et al. CCR9/CCL25 expression in nonsmall cell lung cancer correlates with aggressive disease and mediates key steps of metastasis［J］. Oncotarget, 2014, 5(20): 1017010179. DOI: 10.18632/oncotarget.2526. ［21］ Ploenes T, Scholtes B, Krohn A, et al. CCchemokine ligand 18 induces epithelial to mesenchymal transition in lung cancer A549 cells and elevates the invasive potential［J］. PLoS One, 2013, 8(1): e53068. DOI: 10.1371/journal.pone.0053068. ［22］ Dai X, Mao Z, Huang J, et al. The CXCL12/CXCR4 autocrine loop increases the metastatic potential of nonsmall cell lung cancer in vitro［J］. Oncol Lett, 2013, 5(1): 277282. DOI: 10.3892/ol.2012.960. ［23］ Choi YH, Burdick MD, Strieter BD, et al. CXCR4, but not CXCR7, discriminates metastatic behavior in nonsmall cell lung cancer cells［J］. Mol Cancer Res, 2014, 12(1): 3847. DOI: 10.1158/15417786.MCR120334. ［24］ Xie S, Zeng W, Fan G, et al. Effect of CXCL12/CXCR4 on increasing the metastatic potential of nonsmall cell lung cancer in vitro is inhibited through the downregulation of CXCR4 chemokine receptor expression［J］. Oncol Lett, 2014, 7(4): 941947. DOI: 10.3892/ol.2014.1837. ［25］ Wang L, Wang Z, Liu X, et al. Highlevel CXC chemokine receptor type 4 expression correlates with brainspecific metastasis following complete resection of nonsmall cell lung cancer［J］. Oncol Lett, 2014, 7(6): 18711876. DOI: 10.3892/ol.2014.1979. ［26］ Kee JY, Arita Y, Shinohara K, et al. Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo［J］. Mol Clin Oncol, 2013, 1(1): 3540. DOI: 10.3892/mco.2012.30. ［27］ Baratelli F, Takedatsu H, Hazra S, et al. Preclinical characterization of GMP grade CCL21gene modified dendritic cells for application in a phase Ⅰ trial in nonsmall cell lung cancer［J］. J Transl Med, 2008, 6: 38. DOI: 10.1186/14795876638. ［28］ Kar UK, Srivastava MK, Andersson A, et al. Novel CCL21vault nanocapsule intratumoral delivery inhibits lung cancer growth［J］. PLoS One, 2011, 6(5): e18758. DOI: 10.1371/journal.pone.0018758. ［29］ Wald O, Shapira OM, Izhar U. CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential［J］. Theranostics, 2013, 3(1): 2633. DOI: 10.7150/thno.4922.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[3]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[4]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[5]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[6]	孙国宝, 杨倩, 庄庆春, 高斌斌, 孙晓刚, 宋伟, 沙丹. 结直肠癌肝转移组织病理学生长方式研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 114-118.
[7]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[8]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[9]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[10]	张露, 蒋华, 林州, 马辰莺, 徐晓婷, 王利利, 周菊英. 免疫检查点抑制剂治疗复发转移性宫颈癌的疗效及预后分析[J]. 国际肿瘤学杂志, 2023, 50(8): 475-483.
[11]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[12]	张丽, 向卓, 王强, 毕经旺. CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[13]	杨丽蓉, 王羽丰. 预测浆液性卵巢癌术后复发远处转移风险机器学习模型的构建[J]. 国际肿瘤学杂志, 2023, 50(4): 220-226.
[14]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[15]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.